Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Clinical evidence

Explore-CKD

68 evidence topics · 10 sources

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Primary purpose“Treatment”
Allocation“Randomized”
Interventional model“Crossover Assignment”
Phase“Phase 2”
Enrollment (actual)“60”
Eligibility criteria
Treatment
Study outcomes
Rationale for using change in automated office systolic blood pressure as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed in the posted results
AnalysisPlaceboLorundrostat
Primary outcome, overall number of participants analyzed“58”“58”
All-cause mortality, affected / at risk (%)“0/57 (0.00%)”“0/58 (0.00%)”
Description of analysis sets
Results
Participant disposition
Participant flow in the posted results
MilestoneCohort 1 (lorundrostat, then placebo)Cohort 2 (placebo, then lorundrostat)
Started“30”“29”
Completed“29”“28”
Not completed“1”“1”
Reason not completed: physician decision“1”“1”
Baseline characteristics
Baseline characteristics table (N = 59)
CharacteristicValue
Age, years, mean ± SD“64.6 ± 10.14”
Age 75 years or older, n (%)“13 (22.0)”
Male, n (%)“41 (69.5)”
Female, n (%)“18 (30.5)”
White, n (%)“39 (66.1)”
Black or African American, n (%)“10 (16.9)”
Hispanic or Latino, n (%)“25 (42.4)”
Body mass index, kg/m2, mean ± SD“33.1 ± 7.10”
Seated automated office systolic blood pressure, mm Hg, mean ± SD“148.9 ± 10.37”
Seated automated office diastolic blood pressure, mm Hg, mean ± SD“82.0 ± 10.49”
eGFR (cystatin C), ml/min per 1.73 m2, mean ± SD“43.0 ± 14.97”
eGFR (creatinine), ml/min per 1.73 m2, mean ± SD“54.6 ± 21.08”
UACR (24 hr), mg/g, geometric mean ± SD“559 ± 2.55”
Two or fewer antihypertensive medications, n (%)“21 (35.6)”
Three or more antihypertensive medications, n (%)“38 (64.4)”
β-Blockers, n (%)“28 (47.5)”
Selective calcium-channel blockers with mainly vascular effects, n (%)“30 (50.8)”
Type 2 diabetes mellitus, n (%)“45 (76.3)”
SGLT2i-naive at screening, n (%)“26 (44.1)”
Baseline systolic blood pressure by sequence in the posted results
GroupSeated automated office systolic blood pressure, mmHg, mean (SD)
Cohort 1 (lorundrostat, then placebo)“147.008(9.8704)”
Cohort 2 (placebo, then lorundrostat)“150.802(10.6962)”
Total“148.873(10.3731)”
Efficacy results
Primary outcome in the posted results
MeasurePlaceboLorundrostat
Least squares mean change from baseline, mmHg“-1.755”“-9.253”
90% confidence interval“(-4.966 to 1.455)”“(-12.453 to -6.053)”
Topline results table in the sponsor release
MeasurePlaceboLorundrostat 25 mgPlacebo-adjusted
Change in systolic BP (mmHg), primary endpoint“-1.76”“-9.25”“-7.5 (p=0.0024)”
Change in spot UACR (mg/g)“-6.60%”“-30.51%”“-25.60% (p=0.0015)”
Change in eGFR, cystatin C (mL/min/1.73m2)“-2.20%”“-6.78%”“-4.58% (p=0.0362)”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Overview of treatment-emergent adverse events, n (%) and number of events
EventPlacebo (n = 57)Lorundrostat (n = 58)
TEAEs“19 (33.3) [36]”“29 (50.0) [54]”
Treatment-related TEAEs“8 (14.0) [9]”“16 (27.6) [24]”
Serious adverse events“0 (0.0) [0]”“2 (3.4) [4]”
Adverse events of special interest“1 (1.8) [1]”“10 (17.2) [13]”
TEAEs leading to discontinuation of the trial drug“1 (1.8) [1]”“2 (3.4) [3]”
TEAEs leading to dose modification of the trial drug“4 (7.0) [4]”“12 (20.7) [15]”
Death“0 (0.0) [0]”“0 (0.0) [0]”
Participants with at least 1 confirmed elevated potassium value, n (%)
Prespecified levelPlacebo (n = 57)Lorundrostat (n = 58)
Level 1: >5.5–6.0 mmol/l“1 (1.8)”“4 (6.9)”
Level 2: >6.0–6.5 mmol/l“0 (0.0)”“2 (3.4)”
Level 3: >6.5 mmol/l“0 (0.0)”“1 (1.7)”
Serious adverse events in the posted results
EventPlacebo, affected / at risk (%)Lorundrostat, affected / at risk (%)
Total“0/57 (0.00%)”“2/58 (3.45%)”
Influenza“0/57 (0.00%)”“1/58 (1.72%)”
Hyperkalaemia“0/57 (0.00%)”“1/58 (1.72%)”
Acute kidney injury“0/57 (0.00%)”“1/58 (1.72%)”
Other adverse events in the posted results (frequency threshold 2%)
EventPlacebo, affected / at risk (%)Lorundrostat, affected / at risk (%)
Total“18/57 (31.58%)”“29/58 (50.00%)”
Glomerular filtration rate decreased“2/57 (3.51%)”“6/58 (10.34%)”
Hyperkalaemia“2/57 (3.51%)”“9/58 (15.52%)”
Hyponatraemia“3/57 (5.26%)”“3/58 (5.17%)”
Hypotension“2/57 (3.51%)”“3/58 (5.17%)”
Orthostatic hypotension“1/57 (1.75%)”“2/58 (3.45%)”
Diastolic hypotension“1/57 (1.75%)”“2/58 (3.45%)”
Study limitations
Summary

Explore-CKD was a phase 2, two-period, two-sequence crossover trial with 4-week treatment periods separated by a 4-week washout. The publication reports 59 randomized participants at 42 sites in the United States; the registry lists an enrollment of 60 and 44 locations. One dose, lorundrostat 25 mg once daily, was studied. The primary endpoint was the placebo-adjusted change in automated office systolic blood pressure; albuminuria, proteinuria, and eGFR were exploratory endpoints, and no kidney or cardiovascular outcome was assessed. The investigators state that the 4-week treatment period “does not assess the durability of blood pressure lowering or longer-term safety and clinical outcomes” and that the findings “will require confirmation in a larger, longer-duration, parallel-arm trial”. Participants with serum potassium above 5.0 mmol/L at screening were excluded, which, with the short treatment duration, the investigators state “could underestimate hyperkalemia risk in routine clinical practice”; hyperkalemia was reported in 9 of 58 participants (15.5%) during lorundrostat treatment and 2 of 57 (3.5%) during placebo. The registry requires stable ACEi or ARB treatment for at least 2 months before screening, and the publication states at least 4 weeks. The trial was designed and funded by Mineralys Therapeutics, three authors are company employees, and no health-related quality of life or patient-reported outcome was reported.